Annovis Bio Receives U.S. Patent for New Crystalline Form of Buntanetap

PUBT · 2d ago
Annovis Bio Receives U.S. Patent for New Crystalline Form of Buntanetap
  • Annovis Bio received a U.S. patent November 3, 2026, covering buntanetap Form B, with protection through June 21, 2044.
  • Form B is used in the fully enrolled pivotal Phase 3 Alzheimer's trial and an open-label Parkinson's extension study.
  • The Alzheimer's trial has symptomatic results expected in Q1 2027, followed by disease-modifying results in Q1 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611120800PRIMZONEFULLFEED9875854) on November 12, 2026, and is solely responsible for the information contained therein.